Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Chief Financial Officer | June 09, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date June 09, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,867 |
Last balance in matching sequence
After 2026-06-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-09 · Exercise / conversion · Acquired 33,000 · Balance 75,867 F1: Represents an exercise of stock options which was held for over 8 years and exercised prior to the 10-year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F5: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. Row 2 · 2026-06-09 · Sale · Disposed 33,000 · Balance 42,867 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.46 and $242.35. F5: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.50 · Expires 2028-05-16 | Direct | 72,000 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Exercise / conversion · Disposed 33,000 · Balance 72,000 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. |
| Common StockSEC Table I · non-derivative | IndirectSee explanation 6 below. | 488 |
Reported balance
Holding disclosure · report date 2026-06-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 488 F6: Represents additional shares indirectly beneficially owned by the reporting person as custodian for his children's UTMA accounts. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an exercise of stock options which was held for over 8 years and exercised prior to the 10-year expiration date of such options.
F2: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.46 and $242.35.
F5: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan.
F6: Represents additional shares indirectly beneficially owned by the reporting person as custodian for his children's UTMA accounts.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001193125-26-264035 · ownership.xml · derivative · entry 4 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 33,000 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 33,000 | $240.09 | $7,922,970.00 |
DisclosureSEC source: 0001193125-26-264035 · ownership.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,867 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.46 and $242.35. F5 · balance_after: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 33,000 | $3.50 | $115,500.00 |
DisclosureSEC source: 0001193125-26-264035 · ownership.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for over 8 years and exercised prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F5 · balance_after: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 21, 2026 Filed Apr 24, 2026 01:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 8,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-174412 · ownership.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,188 Underlying: Common Stock · 8,188 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. F2 · derivative.expiration_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:10 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 18,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-083608 · ownership.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,570 Underlying: Common Stock · 18,570 shares Expires 2036-02-26 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001193125-26-021378 · ownership.xml · derivative · entry 4 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 12,000 | $187.92 | $2,255,040.00 |
DisclosureSEC source: 0001193125-26-021378 · ownership.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,588 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $185.09 and $191.12. F5 · balance_after: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 12,000 | $3.50 | $42,000.00 |
DisclosureSEC source: 0001193125-26-021378 · ownership.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for 8 years and exercised prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F5 · balance_after: Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 00:54 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 9,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027070 · ownership.xml · derivative · entry 3 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,423 Underlying: Common Stock · 9,423 shares Expires not disclosed F4 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. F5 · derivative.expiration_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:54 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 9,423 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027070 · ownership.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,423 Underlying: Common Stock · 9,423 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:54 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,516 | $0.00 Strike: $137.75 | $0.00 |
DisclosureSEC source: 0000950170-25-027070 · ownership.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,516 Underlying: Common Stock · 9,516 shares Expires 2035-02-20 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029. Read SEC document |
| February 14, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $3.50 Strike: $3.50 | $10,500.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · derivative · entry 7 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| February 14, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 3,000 | $131.07 | $393,210.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · nonDerivative · entry 4 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,187 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $130.06 and $131.72. Read SEC document |
| February 14, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 3,000 | $3.50 | $10,500.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · nonDerivative · entry 3 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| February 13, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $3.50 Strike: $3.50 | $42,000.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · derivative · entry 6 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| February 13, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 12,000 | $129.86 | $1,558,320.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,187 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $128.50 and $131.64. Read SEC document |
| February 13, 2025 Filed Feb 15, 2025 02:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 12,000 | $3.50 | $42,000.00 |
DisclosureSEC source: 0000950170-25-021716 · ownership.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which was held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:25 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 15,774 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023364 · ownership.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,774 Underlying: Common Stock · 15,774 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:25 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 28,722 | $0.00 Strike: $84.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023364 · ownership.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,722 Underlying: Common Stock · 28,722 shares Expires 2034-02-26 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:14 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 20,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016457 · doc4.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,554 Underlying: Common Stock · 20,554 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:14 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,246 | $0.00 Strike: $65.32 | $0.00 |
DisclosureSEC source: 0001209191-23-016457 · doc4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,246 Underlying: Common Stock · 36,246 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 41,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017158 · doc4.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,176 Underlying: Common Stock · 41,176 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,872 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001209191-22-017158 · doc4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,872 Underlying: Common Stock · 77,872 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:31 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 142 | $35.20 | $4,998.40 |
DisclosureSEC source: 0001209191-21-066005 · doc4.xml · nonDerivative · entry 4 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA account Disclosed balance after: 142 F5 · ownership.nature: Represents 142 shares of common stock indirectly held by the reporting person as custodian for his other son's UTMA account. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:31 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 145 | $34.30 | $4,973.50 |
DisclosureSEC source: 0001209191-21-066005 · doc4.xml · nonDerivative · entry 3 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA account Disclosed balance after: 145 F4 · ownership.nature: Represents 145 shares of common stock indirectly held by the reporting person as custodian for his daughter's UTMA account. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:31 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 141 | $35.43 | $4,995.63 |
DisclosureSEC source: 0001209191-21-066005 · doc4.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA account Disclosed balance after: 201 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.42 to $35.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents 141 shares of common stock indirectly held by the reporting person as custodian for his son's UTMA account. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other 4. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 12:31 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 527 | $35.50 | $18,708.50 |
DisclosureSEC source: 0001209191-21-066005 · doc4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,789 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.39 to $35.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 00:55 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,086 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001209191-21-064589 · doc4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,086 Underlying: Common Stock · 36,086 shares Expires 2031-11-11 F1 · derivative.exercise_date: The option will start to vest one year from November 12, 2021 and then will vest in substantially equal quarterly installments over three years such that the option will be fully vested on November 12, 2025. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:48 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 19,208 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-010811 · doc4.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,208 Underlying: Common Stock · 19,208 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 5, 2025. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:48 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 36,086 | $0.00 Strike: $65.02 | $0.00 |
DisclosureSEC source: 0000899243-21-010811 · doc4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,086 Underlying: Common Stock · 36,086 shares Expires 2031-03-04 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 5, 2025. Read SEC document |
| June 29, 2020 Filed Jun 30, 2020 12:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 777 | $76.64 | $59,549.28 |
DisclosureSEC source: 0001104659-20-078440 · a4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,217 F1 · shares: 777 shares were purchased by the Reporting Person's IRA. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 18,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004011 · edgar.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,645 Underlying: Common Stock · 18,645 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 17, 2020 Filed Mar 20, 2020 01:19 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,880 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001179110-20-004011 · edgar.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,880 Underlying: Common Stock · 60,880 shares Expires 2030-03-16 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024. Read SEC document |
| March 17, 2020 Filed Dec 23, 2020 23:08 UTC Amendment | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 14,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-139274 · tm2039202-1_4seq1.xml · derivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,767 Underlying: Common Stock · 14,767 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 17, 2024. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 17, 2020 Filed Dec 23, 2020 23:08 UTC Amendment | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 48,237 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001104659-20-139274 · tm2039202-1_4seq1.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,237 Underlying: Common Stock · 48,237 shares Expires 2030-03-16 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 17, 2024. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:43 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (right to buy) · Derivative | 25,813 | $0.00 Strike: $17.61 | $0.00 |
DisclosureSEC source: 0001179110-19-011012 · edgar.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,813 Underlying: Common Stock · 25,813 shares Expires 2029-10-09 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on October 10, 2023; provided, that the vesting of the option will be accelerated such that 100% of the option will become fully vested upon the achievement of certain clinical, operational, and/or other milestones (approved by the compensation committee) prior to, on, or about December 31, 2019. Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 11:16 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 2,180 | $24.80 | $54,064.00 |
DisclosureSEC source: 0001104659-19-051908 · a4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,440 F1 · shares: 2,000 shares were purchased by the Reporting Person's Roth IRA and 180 shares were purchased by the Reporting Person's IRA. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 11:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 1,920 | $20.80 | $39,936.00 |
DisclosureSEC source: 0001104659-19-034903 · a4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920 Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:07 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (right to buy) · Derivative | 75,102 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001104659-19-016571 · a4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,102 Underlying: Common Stock · 75,102 shares Expires 2029-03-18 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 19, 2023. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 5,340 | $12.58 | $67,177.20 |
DisclosureSEC source: 0001104659-19-016424 · a4.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,340 F2 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $12.57 to $12.59, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 60 | $12.69 | $761.40 |
DisclosureSEC source: 0001104659-19-016424 · a4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By UTMA account Disclosed balance after: 60 F1 · ownership.direct: Represents 60 shares of common stock purchased by the reporting person as custodian for his son's UTMA account. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 30,600 | $3.10 | $94,860.00 |
DisclosureSEC source: 0001104659-18-041289 · a4.xml · nonDerivative · entry 2 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 21:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 400 | $3.05 | $1,220.00 |
DisclosureSEC source: 0001104659-18-041289 · a4.xml · nonDerivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Read SEC document |
| May 16, 2018 Filed May 29, 2018 21:32 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (right to buy) · Derivative | 132,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001104659-18-036457 · a4.xml · derivative · entry 1 Pizzie Nick · CIK 0001742143 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2015 Omnibus Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 75% in equal increments on a quarterly basis for three years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.